The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial

Hoeger, Peter H.; Kh, Lee; Jautová, J; Wohlrab, Johannes; Guettner, A.; Mizutani, G.; Hultsch, T.

doi:10.1111/j.1365-2133.2008.08928.x

Cited by 42 publications

(45 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The remaining 21 articles met all entry criteria and were included in the network meta-analysis. Among these studies, 3 articles were dual submissions and 1 study was divided into two comparisons; thus, only 19 [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25] treatment comparisons were included. The screening process is illustrated in figure 2.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

Huang

2015

Dermatology

View full text Add to dashboard Cite

Objective: Using a network meta-analysis, we aimed to compare the efficacy and safety of tacrolimus and pimecrolimus as treatment options for children with atopic dermatitis (AD). Methods: Randomized controlled studies with a modified Jadad score >3 using tacrolimus or pimecrolimus in pediatric patients with AD were studied. Results: Out of 163 articles, 19 studies enrolling a total of 6,413 pediatric patients were selected. Pooled analysis revealed that tacrolimus 0.03% or 0.1% and pimecrolimus 1% were better at reducing eczema compared with vehicles. No significance was found between tacrolimus and pimecrolimus in improving the severity of eczema. More patients tended to withdraw in the vehicle groups compared to the tacrolimus and pimecrolimus groups. No significant difference existed between total adverse events and withdrawals in the tacrolimus and pimecrolimus groups. Conclusions: Pimecrolimus was similar to tacrolimus in both efficacy and safety for AD in children, but both were better than vehicles.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

Huang

2015

Dermatology

View full text Add to dashboard Cite

show abstract

“…Topical pimecrolimus was generally well tolerated in shortterm (£6 weeks), continuous-use trials [16][17][18][19] and longer term (1-2 years), intermittent-use trials [4,5,21,22] in pediatric patients with mild to moderate atopic dermatitis. According to pooled double-blind data, [37,38] the incidences of the majority of the most frequently reported adverse events were not significantly different between topical pimecrolimus and vehicle groups.…”

Section: Tolerabilitymentioning

confidence: 97%

“…[15] 2. Therapeutic Efficacy Twice-daily topical pimecrolimus was superior to vehicle in controlling the symptoms of atopic dermatitis in pediatric patients in 4- [16] or 6-week, [17][18][19] randomized, double-blind, multicenter trials as assessed by the improvement in the Investigator's Global Assessment (IGA) scale or the Eczema Area and Severity Index (EASI). The change from baseline at study end in IGA scores was not significantly different between the topical pimecrolimus group and the topical tacrolimus 0.03% ointment (hereafter topical tacrolimus) group in a 6-week, randomized, investigator-blind, multicenter trial.…”

Section: Pharmacologic Propertiesmentioning

confidence: 99%

“…Comparative tolerability data from a short-term, continuoususe trial involving topical pimecrolimus and topical tacrolimus show that the two agents were generally similar. [20] Serious adverse events [4,16,18,22,39,40] or withdrawal from study as a consequence of adverse events [16][17][18]39,41] were infrequent. Currently available data [37,38,[42][43][44][45][46][47][48] do not support an increased risk of malignancy or systemic immunosuppression with the use of topical pimecrolimus; however, its long-term safety beyond 1-2 years is yet to be established.…”

Section: Tolerabilitymentioning

confidence: 99%

See 1 more Smart Citation

Spotlight on Topical Pimecrolimus in Pediatric Atopic Dermatitis†

Yang

Curran

2010

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Topical pimecrolimus 1% cream (Elidel) [hereafter referred to as topical pimecrolimus] is a nonsteroidal alternative in the treatment of pediatric atopic dermatitis. In vehicle-controlled, short-term, continuous-use trials in pediatric patients with mild to moderate atopic dermatitis, topical pimecrolimus was effective in treating disease symptoms. Topical pimecrolimus was effective in preventing disease flares and reducing the need for topical corticosteroids in longer term, intermittent-use trials. In addition, topical pimecrolimus was associated with improvements in the health-related quality of life of pediatric patients with atopic dermatitis and their parents. In vehicle-controlled trials, topical pimecrolimus was generally as well tolerated as vehicle. Topical pimecrolimus showed similar efficacy to topical tacrolimus 0.03% ointment in a short-term, continuous-use trial and the two agents had a generally similar tolerability profile. Although comparative data between topical pimecrolimus and topical corticosteroids are lacking in pediatric patients, and the long-term tolerability (beyond 1-2 years) of topical pimecrolimus is yet to be established, topical pimecrolimus is a useful agent in the management of pediatric patients with mild to moderate atopic dermatitis who do not achieve satisfactory treatment with other topical pharmacologic treatments, including topical corticosteroids.

show abstract

“…It can also be used for treatment of sensitive skin (e.g. face and other sensitive skin areas, skin of infants), as it has no atrophogenic potential [3,4,5]. In addition, pimecrolimus cream reduces the requirement of topical corticosteroids in the management of severe pediatric AD [6].…”

Section: Introductionmentioning

confidence: 99%

Percutaneous Absorption of Pimecrolimus Is Not Increased in Patients with Moderate to Severe Atopic Dermatitis when Pimecrolimus Cream 1% Is Applied under Occlusion

Thaçi

Kaufmann²,

Bieber³

et al. 2010

Dermatology

View full text Add to dashboard Cite

Aim: To evaluate the systemic exposure of pimecrolimus cream 1% applied under occlusion in atopic dermatitis (AD) patients. Methods: A noncomparative, open-label study conducted in 3 groups of moderate to severe AD patients: A (adults, n = 9), B (adolescents, n = 4) and C (children, n = 6). Pimecrolimus cream 1% was applied twice daily for 8.5 days with overnight occlusion in patients with investigator’s global assessment scores of ≧3 and AD involving at least 30% of their body surface area. Pimecrolimus blood concentrations were analyzed. Results: The highest pimecrolimus blood concentrations observed in adults, adolescents and children were 1.84, 0.55 and 1.29 ng/ml, respectively. Pimecrolimus blood concentrations and affected body surface area showed no apparent correlation. Conclusion: No measurable differences were found in pimecrolimus blood concentrations, efficacy and safety profile when pimecrolimus cream 1% was applied under occlusion versus application without occlusion. These findings reflect the high lipophilic properties of pimecrolimus.

show abstract

The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial

Cited by 42 publications

References 30 publications

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

Spotlight on Topical Pimecrolimus in Pediatric Atopic Dermatitis†

Percutaneous Absorption of Pimecrolimus Is Not Increased in Patients with Moderate to Severe Atopic Dermatitis when Pimecrolimus Cream 1% Is Applied under Occlusion

Contact Info

Product

Resources

About